Cabio Biotech Wuhan Co Ltd (688089) — Cash Flow Quality Index
Cabio Biotech Wuhan Co Ltd (688089) has a Cash Flow Quality Index of 2.62x as of September 2025. Operating cash flow of CN¥56.10 Million exceeds net income of CN¥21.39 Million, indicating high earnings quality where cash backs reported profits. Explore Cabio Biotech Wuhan Co Ltd cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cabio Biotech Wuhan Co Ltd Cash Flow Quality Index (2013–2024)
Historical Cash Flow Quality Index for Cabio Biotech Wuhan Co Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 688089 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Cabio Biotech Wuhan Co Ltd (2013–2024)
Year-by-year earnings quality comparison for Cabio Biotech Wuhan Co Ltd. For live market cap and the full company financial profile, see Cabio Biotech Wuhan Co Ltd stock valuation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.44x | CN¥173.04 Million | CN¥120.13 Million | ▲ +91.1% |
| 2023 | 0.75x | CN¥68.89 Million | CN¥91.37 Million | ▼ -73.7% |
| 2022 | 2.86x | CN¥176.40 Million | CN¥61.59 Million | ▲ +264.1% |
| 2021 | 0.79x | CN¥103.29 Million | CN¥131.29 Million | ▼ -27.2% |
| 2020 | 1.08x | CN¥145.88 Million | CN¥134.94 Million | ▼ -1.9% |
| 2019 | 1.10x | CN¥131.95 Million | CN¥119.75 Million | ▲ +1.5% |
| 2018 | 1.09x | CN¥106.16 Million | CN¥97.83 Million | ▼ -29.3% |
| 2017 | 1.53x | CN¥100.66 Million | CN¥65.59 Million | ▲ +13.8% |
| 2016 | 1.35x | CN¥62.53 Million | CN¥46.35 Million | ▼ -40.9% |
| 2015 | 2.28x | CN¥44.58 Million | CN¥19.55 Million | ▲ +85.4% |
| 2014 | 1.23x | CN¥46.34 Million | CN¥37.66 Million | ▲ +45.6% |
| 2013 | 0.85x | CN¥39.48 Million | CN¥46.70 Million | — |